Cadila Healthcare has come up as the frontrunner to acquire the generic sterile injectables business of Ahmedabad-headquartered Claris Lifesciences Ltd (CLL).
As per sources, the last minutes negotiations are underway between the both companies, including tax and other financial matters. A formal announcement is expected next month as the deal has not yet closed.
Cadila Healthcare, the Zydus Cadila Group flagship, is likely to pay a significant premium, valuing the company between Rs 3,100 crore – Rs 3,400 crore.
For 12 months ending December 31, 2014, Claris Lifesciences business reported revenues of Rs 405.6 crore and EBITDA of Rs 149.4 crore (37% EBITDA margin).
Presently, the market cap of parent Claris Lifesciences including all the different businesses is Rs 1,793 crore.
In recent days, we have seen a lot of major deals in the field of injectables – Pfizer – Hospira, Endo-Par Pharmaceuticals, Mylan – Strides injectable business Agila Specialities.